Human Anti-Marburg (Angola) glycoprotein (GP) IgG ELISA Kit

Sample

Serum, plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

The Human Anti-Marburg Virus Glycoprotein (MARV GP) IgG ELISA Kit is an immunoassay suitable for quantifying IgG antibody activity specific for Marburg virus glycoprotein in serum or plasma of vaccinated, immunized, and/or infected hosts.

This immunoassay is suitable for:
Determining immune status relative to non-immune controls
Assessing efficacy of vaccines, including dosage, adjuvantcy, route of immunization, and timing
Qualifying and standardizing vaccine batches & protocols

The assay is for research use only (RUO) and is not intended nor validated for diagnosing Marburg virus disease. Reagents contain no virus or viral antigens.

Contents of Kit

1. Wash Solution Concentrate (100×): 10ml. Dilute the entire volume 10ml + 990ml with distilled or deionized water into a clean stock bottle. Label as Working Wash Solution and store at 4°C for long term and ambient temp. for short term.
2. Sample Diluent Concentrate (20×): 10ml. Dilute the entire volume, 10ml + 190ml with distilled or deionized water into a clean stock bottle. Label as Working Sample/Conjugate Diluent and store at 2-8°C until the kit lot expires or is used up.
3. Anti-Human IgG-HRP Conjugate Concentrate (100×): 0.15ml. Peroxidase conjugated anti-human IgG in buffer with detergents and antimicrobial as stabilizers. Dilute fresh as needed; 10ul of concentrate to 1ml of Working Sample/Conjugate Diluent is sufficient for 1 8-well strip. Use within the working day and discard. Return 100× to 2-8°C storage.
4. MARV GP Coated Strip Plate
5. Anti-MARV GP Calibrators, 4vials×0.65ml. 1 U/ml, 2.5 U/ml, 5 U/ml, 10 U/ml.
6. Anti-MARV GP Positive Control, 0.65 ml
7. Low NSB Sample Diluent, 30 ml
8. TMB Substrate, 12 ml
9. Stop Solution, 12 ml

Storage

The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label.

General Description

Marburg virus (MARV) is a hemorrhagic fever virus of the Filoviridae family of viruses, which causes Marburg virus disease (MVD), a form of viral hemorrhagic fever (MHF), in humans and nonhuman primates. Marburg virus was first noticed in the German cities Marburg and Frankfurt. Most recent outbreaks of MVD occurred in Uganda in 2014. Old World fruit bats appear to be involved in the natural maintenance of MARV. MARV contain non-infectious, linear non-segmented, ssRNA genomes of ~19 kb that codes for 7 genes in the order 3'-UTR-NP-VP35-VP40-GP-VP30-VP24-L-5'-UTR. The genomes of the two different Marburg viruses (MARV and RAVV) differ in sequence. Like all filoviruses, Marburg virions are filamentous particles. Marburg virions consist of seven structural proteins. At the center is the helical ribonucleocapsid, which consists of the genomic RNA wrapped around a polymer of nucleoproteins (NP). Associated with the ribonucleoprotein is the RNA-dependent RNA polymerase (L) with the polymerase cofactor (VP35) and a transcription activator (VP30). The ribonucleoprotein is embedded in a matrix, formed by the major (VP40) and minor (VP24) matrix proteins. These particles are surrounded by a lipid membrane derived from the host cell membrane. The membrane anchors a glycoprotein (GP1,2) that projects 7 to 10 nm spikes away from its surface. While nearly identical to Ebola virions in structure, Marburg virions are antigenically distinct. Viral proteins (NP, GP, and VP40) are highly immunogenic and could individually or together constitute effective vaccines. Promising vaccine candidates include DNA vaccines or those based on adenoviruses, vesicular stomatitis Indiana virus (VSIV) or filovirus-like particles (VLPs) as all of these candidates could protect nonhuman primates from virus-induced disease.